Clinicians Medication overview

FDA approval of oral Wegovy

Originally posted Dec 2025 · By Joe Zucchi, PA-C, MPAS

Download PNG ↓Original LinkedIn post ↗

1536 × 1536 px · PDF includes the original image and a link to this page.

Joe’s original LinkedIn post

About this visual

An approval-day visual on the 25 mg daily semaglutide tablet, OASIS 4 results, administration, and its adult weight-management and cardiovascular indications.

The FDA has officially approved oral Wegovy (semaglutide): the first oral GLP-1 receptor agonist specifically approved for chronic weight management.

A few major takeaways:
• Indication: Adults with obesity, or overweight with ≥1 weight-related comorbidity
• Additional indication: CV risk reduction in adults with established cardiovascular disease and overweight/obesity
• Efficacy: ~16.6% mean weight loss in OASIS 4 among patients adherent to treatment
• Dosing: Once-daily oral tablet with stepwise titration up to 25 mg daily
• Administration: Taken on an empty stomach with ≤4 oz water; wait ≥30 minutes before food or other meds
• Availability: Expected early January 2026
• Pricing: Reportedly starting around $149/month for initial dose

This approval expands how we can deliver evidence-based obesity care, especially for patients who prefer an oral option or struggle with injectables.

Big moment for access, choice, and long-term cardiometabolic risk reduction!

I made another infographic for a quick clinical snapshot.

#ObesityMedicine #GLP1 #Wegovy #CardiometabolicHealth #FDAApproval #WeightManagement #OralWegovy

Sources & further reading

Original LinkedIn post ↗

Further reading: Current Wegovy prescribing information ↗

Further reading: OASIS 4 publication ↗

Approval-day pricing and availability shown in the image are historical and subject to change. The 16.6% figure is the adherence estimand, not the treatment-policy result.

Related visuals

FDA approval of oral Wegovy

Pinch to zoom on touch devices. Open full image ↗